日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors

一项针对晚期实体瘤患者的 ERK 抑制剂 MK-8353 联合帕博利珠单抗的 1b 期研究

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-024-01461-z
Lakhani, Nehal J; Burris, Howard 3rd; Miller, Wilson H Jr; Huang, Mo; Chen, Lin-Chi; Siu, Lillian L
MAPK/ERK
发表日期：2024
文献求助 收藏

Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours

Aurora激酶B抑制剂AZD2811的安全性、耐受性和药代动力学：一项针对晚期实体瘤患者的1期剂量探索研究

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/s41416-023-02185-2
Johnson, Melissa L; Wang, Judy S; Falchook, Gerald; Greenlees, Carol; Jones, Suzanne; Strickland, Donald; Fabbri, Giulia; Kennedy, Caroline; Elizabeth Pease, J; Sainsbury, Liz; MacDonald, Alexander; Schalkwijk, Stein; Szekeres, Philip; Cosaert, Jan; Burris, Howard 3rd
信号转导
发表日期：2023
文献求助 收藏

Drug repositioning in epilepsy reveals novel antiseizure candidates

癫痫药物重新定位揭示出新的抗癫痫候选药物

期刊:Annals of Clinical and Translational Neurology
影响因子:4.4
doi:10.1002/acn3.703
Leo Brueggeman, Morgan L Sturgeon, Russell M Martin, Andrew J Grossbach, Yasunori Nagahama, Angela Zhang, Mathew A Howard 3rd, Hiroto Kawasaki, Shu Wu, Robert A Cornell, Jacob J Michaelson, Alexander G Bassuk
神经
癫痫
发表日期：2018
文献求助 收藏

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

曲妥珠单抗-美坦新联合或不联合帕妥珠单抗与曲妥珠单抗联合紫杉烷类药物治疗人表皮生长因子受体2阳性晚期乳腺癌：III期MARIANNE研究的主要结果

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.2016.67.4887
Perez, Edith A; Barrios, Carlos; Eiermann, Wolfgang; Toi, Masakazu; Im, Young-Hyuck; Conte, Pierfranco; Martin, Miguel; Pienkowski, Tadeusz; Pivot, Xavier; Burris, Howard 3rd; Petersen, Jennifer A; Stanzel, Sven; Strasak, Alexander; Patre, Monika; Ellis, Paul
肿瘤
肿瘤免疫
信号转导
乳腺癌
Human
发表日期：2017
文献求助 收藏

miR-150 promotes renal fibrosis in lupus nephritis by downregulating SOCS1

miR-150通过下调SOCS1促进狼疮性肾炎中的肾纤维化

期刊:Journal of the American Society of Nephrology
影响因子:9.4
doi:10.1681/ASN.2012080849
Zhou, Hua; Hasni, Sarfaraz A; Perez, Paola; Tandon, Mayank; Jang, Shyh-Ing; Zheng, Changyu; Kopp, Jeffery B; Austin, Howard 3rd; Balow, James E; Alevizos, Ilias; Illei, Gabor G
SOCS1
肾炎
发表日期：2013
文献求助 收藏

Susceptibility of Anopheles stephensi to Plasmodium gallinaceum: a trait of the mosquito, the parasite, and the environment

斯氏按蚊对鸡疟原虫的易感性：蚊子、寄生虫和环境的特性

期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0020156
Hume, Jen C C; Hamilton, Howard 3rd; Lee, Kevin L; Lehmann, Tovi
微生物学
发表日期：2011
文献求助 收藏

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

硼替佐米两种剂量治疗复发性多发性骨髓瘤患者的药代动力学和药效学研究

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-010-1283-3
Reece, Donna E; Sullivan, Dan; Lonial, Sagar; Mohrbacher, Ann F; Chatta, Gurkamal; Shustik, Chaim; Burris, Howard 3rd; Venkatakrishnan, Karthik; Neuwirth, Rachel; Riordan, William J; Karol, Michael; von Moltke, Lisa L; Acharya, Milin; Zannikos, Peter; Keith Stewart, A
多发性骨髓瘤
骨髓瘤
发表日期：2011
文献求助 收藏

Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome

一项针对骨髓增生异常综合征患者的新型谷胱甘肽类似物前药——盐酸依扎替司他脂质体注射剂（Telintra，TLK199）的1-2a期多中心剂量递增研究

期刊:Journal of Hematology & Oncology
影响因子:40.4
doi:10.1186/1756-8722-2-20
Raza, Azra; Galili, Naomi; Callander, Natalie; Ochoa, Leonel; Piro, Lawrence; Emanuel, Peter; Williams, Stephanie; Burris, Howard 3rd; Faderl, Stefan; Estrov, Zeev; Curtin, Peter; Larson, Richard A; Keck, James G; Jones, Marsha; Meng, Lisa; Brown, Gail L
发表日期：2009
文献求助 收藏